Controversies in atrial fibrillation

Lancet

Volumn 367, Issue 9506, 2006, Pages 262-272

  Nattel, Stanley ^a   Opie, Lionel H ^b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR; CALCIUM ANTAGONIST; CLOPIDOGREL; DIGOXIN; DILTIAZEM; DIPYRIDAMOLE; FONDAPARINUX; HEPARIN DERIVATIVE; IDRAPARINUX; IRBESARTAN; SOTALOL; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BRAIN ISCHEMIA; CARDIOVERSION; CLINICAL TRIAL; DRUG INHIBITION; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

EID: 30844452012     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68037-9     Document Type: Review

References (98)

1. SG Rockson, GW Albers Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation J Am Coll Cardiol 43 2004 929 935
2. KM Flegel From delirium cordis to atrial fibrillation: historical development of a disease concept Ann Intern Med 122 1995 867 873
3. S Nattel New ideas about atrial fibrillation 50 years on Nature 415 2002 219 226
4. M Haissaguerre, P Jais, DC Shah Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins N Engl J Med 339 1998 659 666
5. H Oral, BP Knight, H Tada Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation Circulation 105 2002 1077 1081
6. L Mary-Rabine, A Albert, TD Pham The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure Circ Res 52 1983 188 199
7. JL Cox, RB Schuessler, HJ D'Agostino Jr The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure J Thorac Cardiovasc Surg 101 1991 569 583
8. E Raanani, A Albage, TE David, TM Yau, S Armstrong The efficacy of the Cox/maze procedure combined with mitral valve surgery: a matched control study Eur J Cardiothorac Surg 19 2001 438 442
9. P Bruins, H te Velthuis, AP Yazdanbakhsh Activation of the complement system during and after cardiopulmonary bypass surgery:postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia Circulation 96 1997 3542 3548
10. AJ Solomon Pharmacological approach for the prevention of atrial fibrillation after cardiovascular surgery Card Electrophysiol Rev 7 2003 172 177
11. S Nattel, P Khairy, D Roy New approaches to atrial fibrillation management: a critical review of a rapidly evolving field Drugs 62 2002 2377 2397
12. SH Hohnloser, KH Kuck, J Lilienthal Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial Lancet 356 2000 1789 1794
13. J Carlsson, S Miketic, J Windeler STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study J Am Coll Cardiol 41 2003 1690 1696
14. IC Van Gelder, VE Hagens, HA Bosker Rate control versus electrical cardioversion for persistent atrial fibrillation study group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation N Engl J Med 347 2002 1834 1840
15. G Opolski, A Torbicki, DA Kosior Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study Chest 126 2004 476 486
16. DG Wyse, AL Waldo, JP DiMarco Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825 1833
17. S de Denus, CA Sanoski, J Carlsson, G Opolski, SA Spinler Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis Arch Intern Med 165 2005 258 262
18. SD Corley, AE Epstein, JP DiMarco Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study Circulation 109 2004 1509 1513
19. LF Hsu, P Jais, P Sanders Catheter ablation for atrial fibrillation in congestive heart failure N Engl J Med 351 2004 2373 2383
20. The AF-CHF Trial Investigators Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial Am Heart J 144 2002 597 607
21. D Roy, M Talajic, P Dorian Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators N Engl J Med 342 2000 913 920
22. BN Singh, SN Singh, DJ Reda Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation N Engl J Med 352 2005 1861 1872
23. JC Hesketh, D Herrera, S Zicha, S Nattel Novel targets for cardiac antiarrhythmic drug development Curr Pharm Des 11 2005 1959 1974
24. S Nattel Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res 54 2002 347 360
25. P Jais, R Weerasooriya, DC Shah Ablation therapy for atrial fibrillation (AF): past, present and future Cardiovasc Res 54 2002 337 346
26. AM Gossage, JA Braxton Hicks On auricular fibrillation Q J Med 6 1913 435 440
27. B Wozakowska-Kaplon, G Opolski Effects of sinus rhythm restoration in patients with persistent atrial fibrillation: a clinical, echocardiographic and hormonal study Int J Cardiol 96 2004 171 176
28. VE Hagens, DJ Van Veldhuisen, O Kamp Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical cardioversion for persistent atrial fibrillation (RACE) study Heart Rhythm 2 2005 19 24
29. IC Van Gelder, DG Wyse, ML Chandler Does intensity of rate control influence outcome in atrial fibrillation? Heart Rhythm 1 suppl 2004 S34 (abstr).
30. B Olshansky, LE Rosenfeld, AL Warner The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation J Am Coll Cardiol 43 2004 1201 1208
31. HA Cooper, DA Bloomfield, DE Bush Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study) Am J Cardiol 93 2004 1247 1253
32. MC Wijffels, CJ Kirchhof, R Dorland, MA Allessie Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats Circulation 92 1995 1954 1968
33. L Yue, J Feng, R Gaspo, GR Li, Z Wang, S Nattel Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation Circ Res 81 1997 512 525
34. K Kumagai, H Nakashima, H Urata, N Gondo, K Arakawa, K Saku Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation J Am Coll Cardiol 41 2003 2197 2204
35. D Li, S Fareh, TK Leung, S Nattel Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort Circulation 100 1999 87 95
36. H Sun, R Gaspo, N Leblanc, S Nattel Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia Circulation 98 1998 719 727
37. H Sun, D Chartier, N Leblanc, S Nattel Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes Cardiovasc Res 49 2001 751 761
38. U Schotten, M Duytschaever, J Ausma, S Eijsbouts, HR Neuberger, M Allessie Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand Circulation 107 2003 1433 1439
39. M Duytschaever, Y Blaauw, M Allessie Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs Cardiovasc Res 67 2005 69 76
40. RG Tieleman, IC Van Gelder, HA Bosker Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? Heart Rhythm 2 2005 223 230
41. M Courtemanche, RJ Ramirez, S Nattel Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model Cardiovasc Res 42 1999 477 489
42. HF Tse, Q Wang, CM Yu, GM Ayers, CP Lau Time course of recovery of left atrial mechanical dysfunction after cardioversion of spontaneous atrial fibrillation with the implantable atrial defibrillator Am J Cardiol 86 2000 1023 1025
43. HF Tse, CP Lau, CM Yu Effect of the implantable atrial defibrillator on the natural history of atrial fibrillation J Cardiovasc Electrophysiol 10 1999 1200 1209
44. C Timmermans, S Levy, GM Ayers Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: observations on treated and nontreated episodes. Metrix Investigators J Am Coll Cardiol 35 2000 1428 1433
45. SP Fynn, DM Todd, WJ Hobbs, KL Armstrong, AP Fitzpatrick, CJ Garratt Clinical evaluation of a policy of early repeated internal cardioversion for recurrence of atrial fibrillation J Cardiovasc Electrophysiol 13 2002 135 141
46. MJ Weigner, LR Thomas, U Patel Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year Am J Med 110 2001 694 702
47. AL Klein, RA Grimm, RD Murray Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N Engl J Med 344 2001 1411 1420
48. G Boriani, M Biffi, I Diemberger, C Martignani, A Branzi Rate control in atrial fibrillation: choice of treatment and assessment of efficacy Drugs 63 2003 1489 1509
49. S Mittal, KM Stein, SM Markowitz, S Iwai, A Guttigoli, BB Lerman An update on electrical cardioversion of atrial fibrillation Card Electrophysiol Rev 7 2003 285 289
50. RL McNamara, LJ Tamariz, JB Segal, EB Bass Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography Ann Intern Med 139 2003 1018 1033
51. S Nattel Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs Cardiovasc Res 37 1998 567 577
52. V Snow, KB Weiss, M LeFevre AAFP Panel on Atrial Fibrillation; ACP Panel on Atrial Fibrillation. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians Ann Intern Med 139 2003 1009 1017
53. M Goldman The management of chronic atrial fibrillation: indications and method of conversion to sinus rhythm Prog Cardiovasc Dis 2 1959 465 479
54. B Lown Electrical reversion of cardiac arrhythmias Br Heart J 29 1967 469 489
55. IA Khan Atrial stunning: basics and clinical considerations Int J Cardiol 92 2003 113 128
56. C Pappone, V Santinelli, F Manguso Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation Circulation 109 2004 327 334
57. A Verma, F Kilicaslan, E Pisano Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction Circulation 112 2005 627 635
58. K Lemola, H Oral, A Chugh Pulmonary vein isolation as an end point for left atrial circumferential ablation of atrial fibrillation J Am Coll Cardiol 46 2005 1060 1066
59. OM Wazni, NF Marrouche, DO Martin Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial JAMA 293 2005 2634 2640
60. PA Wolf, RD Abbott, WB Kannel Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study Arch Intern Med 147 1987 1561 1564
61. HJ Lin, PA Wolf, M Kelly-Hayes Stroke severity in atrial fibrillation. The Framingham Study Stroke 27 1996 1760 1764
62. RM Heppell, KE Berkin, JM McLenachan, JA Davies Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation Heart 77 1997 407 411
63. DS Conway, LA Pearce, BS Chin, RG Hart, GY Lip Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation Circulation 107 2003 3141 3145
64. DE Singer, GW Albers, JE Dalen, AS Go, JL Halperin, WJ Manning Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 suppl 3 2004 S429 S456
65. PMW Bath, L Zhao, S Heptinstall Current status of stroke prevention in patients with atrial fibrillation Eur Heart J 7 suppl C 2005 C12 C18
66. H Voller In defence of current treatment options: where are we now? Eur Heart J 7 suppl E 2005 E4 E9
67. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
68. RG Hart, LA Pearce, R McBride, RM Rothbart, RW Asinger on behalf of the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials Stroke 30 1999 1223 1229
69. Stroke Prevention in Atrial Fibrillation Investigators Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study J Stroke Cerebrovasc Dis 5 1995 147 157
70. BF Gage, AD Waterman, W Shannon, M Boechler, MW Rich, MJ Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
71. AS Go, EM Hylek, Y Chang Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290 2003 2685 2692
72. MN Levine, G Raskob, RJ Beyth, C Kearon, S Schulman Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 suppl 3 2004 S287 S310
73. PSJ Miller, MF Drummond, LK Langkilde, JJV McMurray, M Ögren Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation Eur Heart J 7 suppl C 2005 C41 C54
74. S Vasishta, F Toor, A Johansen, M Hasan Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people Arch Gerontol Geriatr 33 2001 219 226
75. M Man-Son-Hing, A Laupacis Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded Arch Intern Med 163 2003 1580 1586
76. P Petersen Thromboembolic complications in atrial fibrillation Stroke 21 1990 4 13
77. FN Brand, RD Abbott, WB Kannel, PA Wolf Characteristics and prognosis of lone atrial fibrillation. Thirty-year follow-up in the Framingham Study JAMA 254 1985 3449 3453
78. RG Hart, LA Pearce, RM Rothbart, JH McAnulty, RW Asinger, JL Halperin Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators J Am Coll Cardiol 35 2000 183 187
79. RL Page, TW Tilsch, SJ Connolly Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide Circulation 107 2003 1141 1145
80. JM Leung, WH Bellows, NB Schiller Impairment of left atrial function predicts post-operative atrial fibrillation after coronary artery bypass graft surgery Eur Heart J 25 2004 1836 1844
81. SC Stamou, PC Hill, G Dangas Stroke after coronary artery bypass: incidence, predictors, and clinical outcome Stroke 32 2001 1508 1513
82. GJ Taylor, SA Malik, JA Colliver Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting Am J Cardiol 60 1987 905 907
83. CJ Bjerkelund, OM Orning The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation Am J Cardiol 23 1969 208 216
84. MJ Weigner, TA Caulfield, PG Danias, DI Silverman, WJ Manning Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours Ann Intern Med 126 1997 615 620
85. V Fuster, LE Ryden, RW Asinger American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology J Am Coll Cardiol 38 2001 1231 1266
86. J Emmerich, JY Le Heuzey, PMW Bath, SJ Connolly Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice Eur Heart J 7 suppl C 2005 C28 C33
87. Executive steering committee on behalf of the SPORTIF III Investigators Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
88. GW Albers, HC Diener, L Frison SPORTIF executive steering committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 2005 690 698
89. HC Diener, A Lowenthal Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation J Neurol Sci 153 1997 112
90. JG Cleland, AP Coletta, M Lammiman Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE Eur J Heart Fail 7 2005 1070 1075
91. GA Donnan, HM Dewey, BR Chambers Warfarin for atrial fibrillation: the end of an era? Lancet Neurol 3 2004 305 308
92. D Li, K Shinagawa, L Pang Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure Circulation 104 2001 2608 2614
93. JS Healey, A Baranchuk, E Crystal Prevention of atrial fibrillation with Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers a meta-analysis J Am Coll Cardiol 45 2005 1832 1839
94. OD Pedersen, H Bagger, L Kober, C Torp-Pedersen Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 100 1999 376 380
95. E Vermes, JC Tardif, MG Bourassa Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials Circulation 107 2003 2926 2931
96. K Wachtell, M Lehto, E Gerdts Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study J Am Coll Cardiol 45 2005 712 719
97. K Shinagawa, A Shiroshita-Takeshita, G Schram, S Nattel Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone Circulation 107 2003 1440 1446
98. L Calò, L Bianconi, F Colivicchi N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery J Am Coll Cardiol 45 2005 1723 1728